Novel sarsasapogenin-triazolyl hybrids as potential anti-Alzheimer's agents: Design, synthesis and biological evaluation. 2018

Wenbao Wang, and Wei Wang, and Guodong Yao, and Qiang Ren, and Di Wang, and Zedan Wang, and Peng Liu, and Pinyi Gao, and Yan Zhang, and Shaojie Wang, and Shaojiang Song
Department of Natural Products Chemistry, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China; Key Laboratory of Structure-Based Drug Design & Discovery (Ministry of Education), Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.

Sarsasapogenin, an active ingredient in Rhizoma anemarrhenae, is a promising bioactive lead compound in the treatment of Alzheimer's disease. To search for more efficient anti-Alzheimer agents, a series of novel sarsasapogenin-triazolyl hybrids were designed, synthesized, and evaluated for their Aβ1-42 aggregation inhibitory activities. Most of these new hybrids displayed potent Aβ1-42 aggregation inhibition. In particular, the promising compounds 6j and 6o displayed a better ability to interrupt the formation of Aβ1-42 fibrils than curcumin. Moreover, 6j and 6o exhibited moderate neuroprotective effects against H2O2-induced neurotoxicity in SH-SY5Y cells. To investigate whether 6j and 6o could improve cognitive deficits, we performed behavioral tests to examine the learning and memory impairments induced by intracerebroventricular injection of Aβ1-42 (ICV-Aβ1-42) in mice and TUNEL staining to observe neuronal apoptosis in the hippocampus. The results obtained indicated that oral treatment with 6j and 6o significantly ameliorated cognitive impairments in behavioral tests and TUNEL staining showed that 6j and 6o attenuated neuronal loss in the brain. Taken together, the results we obtained showed that the sarsasapogenin skeleton could be a promising structural template for the development of new anti-Alzheimer drug candidates, and compounds 6j and 6o have the potential to be important lead compounds for further research.

UI MeSH Term Description Entries
D008297 Male Males
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006624 Hippocampus A curved elevation of GRAY MATTER extending the entire length of the floor of the TEMPORAL HORN of the LATERAL VENTRICLE (see also TEMPORAL LOBE). The hippocampus proper, subiculum, and DENTATE GYRUS constitute the hippocampal formation. Sometimes authors include the ENTORHINAL CORTEX in the hippocampal formation. Ammon Horn,Cornu Ammonis,Hippocampal Formation,Subiculum,Ammon's Horn,Hippocampus Proper,Ammons Horn,Formation, Hippocampal,Formations, Hippocampal,Hippocampal Formations,Hippocampus Propers,Horn, Ammon,Horn, Ammon's,Proper, Hippocampus,Propers, Hippocampus,Subiculums
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013150 Spirostans Cholestane derivatives containing a fused lactone ring at the 16,17-position and a spiroglycosidic linkage at C-22. Members include sarsaponin, DIOSGENIN and yamogenin. Spirostadienes,Spirostanols,Spirostatrienes,Spirostenes
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D016229 Amyloid beta-Peptides Peptides generated from AMYLOID BETA-PEPTIDES PRECURSOR. An amyloid fibrillar form of these peptides is the major component of amyloid plaques found in individuals with Alzheimer's disease and in aged individuals with trisomy 21 (DOWN SYNDROME). The peptide is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue. Alzheimer beta-Protein,Amyloid Protein A4,Amyloid beta-Peptide,Amyloid beta-Protein,beta Amyloid,beta-Amyloid Protein,Alzheimer's ABP,Alzheimer's Amyloid Fibril Protein,Amyloid AD-AP,Amyloid Fibril Protein, Alzheimer's,Amyloid beta-Proteins,ABP, Alzheimer's,AD-AP, Amyloid,Alzheimer ABP,Alzheimer beta Protein,Alzheimers ABP,Amyloid AD AP,Amyloid beta Peptide,Amyloid beta Peptides,Amyloid beta Protein,Amyloid beta Proteins,Amyloid, beta,Protein A4, Amyloid,Protein, beta-Amyloid,beta Amyloid Protein,beta-Peptide, Amyloid,beta-Peptides, Amyloid,beta-Protein, Alzheimer,beta-Protein, Amyloid,beta-Proteins, Amyloid

Related Publications

Wenbao Wang, and Wei Wang, and Guodong Yao, and Qiang Ren, and Di Wang, and Zedan Wang, and Peng Liu, and Pinyi Gao, and Yan Zhang, and Shaojie Wang, and Shaojiang Song
June 2021, European journal of medicinal chemistry,
Wenbao Wang, and Wei Wang, and Guodong Yao, and Qiang Ren, and Di Wang, and Zedan Wang, and Peng Liu, and Pinyi Gao, and Yan Zhang, and Shaojie Wang, and Shaojiang Song
June 2017, Molecules (Basel, Switzerland),
Wenbao Wang, and Wei Wang, and Guodong Yao, and Qiang Ren, and Di Wang, and Zedan Wang, and Peng Liu, and Pinyi Gao, and Yan Zhang, and Shaojie Wang, and Shaojiang Song
December 2022, Chemico-biological interactions,
Wenbao Wang, and Wei Wang, and Guodong Yao, and Qiang Ren, and Di Wang, and Zedan Wang, and Peng Liu, and Pinyi Gao, and Yan Zhang, and Shaojie Wang, and Shaojiang Song
August 2020, Chinese journal of natural medicines,
Wenbao Wang, and Wei Wang, and Guodong Yao, and Qiang Ren, and Di Wang, and Zedan Wang, and Peng Liu, and Pinyi Gao, and Yan Zhang, and Shaojie Wang, and Shaojiang Song
January 2018, Current computer-aided drug design,
Wenbao Wang, and Wei Wang, and Guodong Yao, and Qiang Ren, and Di Wang, and Zedan Wang, and Peng Liu, and Pinyi Gao, and Yan Zhang, and Shaojie Wang, and Shaojiang Song
August 2013, European journal of medicinal chemistry,
Wenbao Wang, and Wei Wang, and Guodong Yao, and Qiang Ren, and Di Wang, and Zedan Wang, and Peng Liu, and Pinyi Gao, and Yan Zhang, and Shaojie Wang, and Shaojiang Song
March 2015, European journal of medicinal chemistry,
Wenbao Wang, and Wei Wang, and Guodong Yao, and Qiang Ren, and Di Wang, and Zedan Wang, and Peng Liu, and Pinyi Gao, and Yan Zhang, and Shaojie Wang, and Shaojiang Song
April 2024, Molecules (Basel, Switzerland),
Wenbao Wang, and Wei Wang, and Guodong Yao, and Qiang Ren, and Di Wang, and Zedan Wang, and Peng Liu, and Pinyi Gao, and Yan Zhang, and Shaojie Wang, and Shaojiang Song
January 2016, Chemical & pharmaceutical bulletin,
Wenbao Wang, and Wei Wang, and Guodong Yao, and Qiang Ren, and Di Wang, and Zedan Wang, and Peng Liu, and Pinyi Gao, and Yan Zhang, and Shaojie Wang, and Shaojiang Song
November 2023, RSC medicinal chemistry,
Copied contents to your clipboard!